Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

Open access
Martin, William H., Hoover, Dennis J., Armento, Sandra J., Stock, Ingrid A., McPherson, R. Kirk, Danley, Dennis E., Stevenson, Ralph W., Barrett, Eugene J., Treadway, Judith L.·1998·Proceedings of the National Academy of Sciences

Abstract

An inhibitor of human liver glycogen phosphorylase a (HLGPa) has been identified and characterized in vitro and in vivo . This substance, [R-(R*,S*)]-5-chloro- N -[3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (CP-91149), inhibited HLGPa with an IC 50 of 0.13 μM in the presence of 7.5 mM glucose. CP-91149 resembles caffeine, a known allosteric phosphorylase inhibitor, in that it is 5- to 10-fold less potent in the absence of glucose. Further analysis, however, suggests that CP-91149 and caffeine are kinetically distinct. Functionally, CP-91149 inhibited glucagon-stimulated glycogenolysis in isolated rat hepatocytes ( P < 0.05 at 10–100 μM) and in primary human hepatocytes (2.1 μM IC 50 ). In vivo , oral administration of CP-91149 to diabetic ob/ob mice at 25–50 mg/kg resulted in rapid (3 h) glucose lowering by 100–120 mg/dl ( P < 0.001) without producing hypoglycemia. Further, CP-91149 treatment did not lower glucose levels in normoglycemic, nondiabetic mice. In ob/ob mice pretreated with 14 C-glucose to label liver glycogen, CP-91149 administration reduced 14 C-glycogen breakdown, confirming that glucose lowering resulted from inhibition of glycogenolysis in vivo. These findings support the use of CP-91149 in investigating glycogenolytic versus gluconeogenic flux in hepatic glucose production, and they demonstrate that glycogenolysis inhibitors may be useful in the treatment of type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.95.4.1776

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 232

Metadata

Authors
Martin, W. H., Hoover, D. J., Armento, S. J., Stock, I. A., McPherson, R. K., Danley, D. E., Stevenson, R. W., Barrett, E. J., & Treadway, J. L.
Venue
Proceedings of the National Academy of Sciences
Published
1998-02-17
Volume
95
Issue
4
Pages
1776-1781
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2001123985
Cited by
232
References
2
FWCI
5.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. https://app.cochat.ai/papers/10.1073/pnas.95.4.1776
The paper
Martin, W. H., Hoover, D. J., Armento, S. J., Stock, I. A., McPherson, R. K., Danley, D. E., Stevenson, R. W., Barrett, E. J., & Treadway, J. L. (1998). Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.95.4.1776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.